**Name of Journal**: *World Journal of Gastroenterology*

**ESPS Manuscript NO**: 26222

**Manuscript Type**: **ORIGINAL ARTICLE**

***Case Control Study***

**Hepatitis C virus G1b infection decreases the number of small low-density lipoprotein particles**

Kinoshita C *et al*. HCV alters the number of lipoproteins

Chika Kinoshita, Tomohisa Nagano, Nobuyoshi Seki, Yoichi Tomita, Tomonori Sugita, Yuta Aida, Munenori Itagaki, Kenichi Satoh, Satoshi Sutoh, Hiroshi Abe, Akihito Tsubota, Yoshio Aizawa

**Chika Kinoshita, Tomohisa Nagano, Nobuyoshi Seki, Yoichi Tomita, Tomonori Sugita, Yuta Aida, Munenori Itagaki, Kenichi Satoh, Satoshi Sutoh, Hiroshi Abe, Yoshio Aizawa,**Department of Gastroenterology and Hepatology Internal Medicine of Jikei University Katsushika Medical Center, Tokyo 125-8506, Japan

**Akihito Tsubota,** Core Research Facilities for Basic Science, Research Center for Medical Science, Jikei University School of Medicine, Tokyo 105-8461, Japan

**Author contributions:** Aizawa Y and Seki N designed research; Kinoshita C, Nagano T, Seki N, Tomita Y, Sugita T, Aida Y, Itagaki M, Sutoh S, Satoh K, Abe H, and Aizawa Y treated patients and collected materials and clinical data; Nagano T, Seki N, and Aizawa Y analyzed data; Aizawa Y and Kinoshita C wrote the paper.

**Supported by** Shionogi Pharmaceutical KK.

**Institutional review board statement:** The study was approved by the ethics committee of Jikei University School of Medicine (Tokyo, Japan). The protocol for this trans-sectional study was approved by the human ethics review committee of the Jikei University School of Medicine (21-032 5610, 1 February 2010, a study of the association between lipoprotein metabolism and pathology in patients with CHC).

**Informed consent statement:** Written informed consent was obtained from all patients enrolled in this study.

**Conflict-of-interest statement:** The authors declare no conflicts of interest.

**Data sharing statement:** Technical appendix, statistical code, and dataset are available from the corresponding author at c.kinoshita.3678@gmail.com. No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to: Chika Kinoshita, MD**, Department of Gastroenterology and Hepatology, Internal Medicine of Jikei University Katsushika Medical Center, 6-41-2 Aoto, Katsushikaku, Tokyo 125-8506, Japan. c.kinoshita.3678@gmail.com

**Telephone:** +81-3360321111-5976

**Fax:** +81-338389944

**Received**: March 30, 2016

**Peer-review started**: April 6, 2016

**First decision**: May 30, 2016

**Revised**: June 11, 2016

**Accepted**: July 6, 2016

**Article in press**:

**Published online**:

**Abstract**

**AIM**: To investigate how hepatitis C virus (HCV) G1b infection influences the particle number of lipoproteins.

**METHODS**: The numbers of lipoprotein particles in fasting sera from 173 Japanese subjects, 82 with active HCV G1b infection (active HCV group) and 91 with cleared HCV infection (SVR group), were examined. Serum lipoprotein was fractionated by high-performance liquid chromatography into twenty fractions. The cholesterol and triglyceride concentrations in each fraction were measured using LipoSEARCH. The number of lipoprotein particles in each fraction was calculated using a newly developed algorithm, and the relationship between chronic HCV G1b infection and the lipoprotein particle number was determined by multiple linear regression analysis.

**RESULTS**: The median number of low-density lipoprotein (LDL) particles was significantly lower in the active HCV group [1182 nmol/L, interquartile range　(IQR): 444 nmol/L] than in the SVR group (1363 nmol/L, IQR: 472 nmol/L, *P* < 0.001), as was that of high-density lipoprotein (HDL) particles (14168 nmol/L *vs* 15054 nmol/L, IQR: 4114 nmol/L *vs* 3385 nmol/L, *P* = 0.042). The number of very low-density lipoprotein (VLDL) particles was similar between the two groups. Among the four LDL sub-fractions, the number of large LDL particles was similar between the two groups. However, the numbers of medium (median: 533.0 nmol/L, IQR: 214.7 nmol/L *vs* median: 633.5 nmol/L, IQR: 229.6 nmol/L, *P* < 0.001), small (median: 190.9 nmol/L, IQR: 152.4 nmol/L *vs* median: 263.2 nmol/L, IQR: 159.9 nmol/L; *P* < 0.001), and very small LDL particles (median: 103.5 nmol/L, IQR: 66.8 nmol/L *vs* median: 139.3 nmol/L, IQR: 67.3 nmol/L, *P* < 0.001) were significantly lower in the active HCV group than in the SVR group, respectively. Multiple linear regression analysis indicated an association between HCV G1b infection and the decreased numbers of medium, small, and very small LDL particles. However, active HCV infection did not affect the number of large LDL particles or any sub-fractions of VLDL and HDL particles.

**CONCLUSION**: HCV G1b infection decreases the numbers of medium, small, and very small LDL particles.

**Key words**: Chronic hepatitis C; Lipoprotein particles; Low-density lipoproteins; Very low-density lipoproteins; Triglycerides; Cholesterol; Regression analysis

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip**: Hepatitis C virus (HCV) infection was previously reported to alter the serum lipid and lipoprotein profiles. However, the effect of HCV on the number of lipoprotein particles was not previously examined because counting the number of lipoprotein particles is challenging. In this report, we investigated how HCV infection changes the particle number of lipoproteins and demonstrated that HCV infection independently decreased the numbers of medium, small, and very small low-density lipoprotein particles. This finding may provide a new perspective on the association between HCV infection and atherosclerosis.

Kinoshita C, Nagano T, Seki N, Tomita Y, Sugita T, Aida Y, Itagaki M, Satoh K, Sutoh S, Abe H, Tsubota A, Aizawa Y. Hepatitis C virus G1b infection decreases the number of small low-density lipoprotein particles. *World J Gastroenterol* 2016; In press

**INTRODUCTION**

Chronic hepatitis C virus (HCV) infection causes liver cirrhosis and hepatic carcinogenesis and is one of the most important health problems in the world. Patients with chronic HCV have lower serum cholesterol levels, which is associated with liver steatosis[1,2], indicating that HCV infection could alter host lipid metabolism. Thus, many studies have attempted to clarify the association between HCV infection and lipid metabolism[3-8].

Lipids are required as an energy source and utilized as an essential component of cellar structure. Hydrophobic lipids are transported to peripheral tissues though blood circulation as water-soluble lipoprotein particles. Lipoproteins are sorted into five classes based on their specific gravity, which is defined by the proportion of triglyceride (TG) and cholesteryl ester (CE) in the core of lipoprotein. These classes are chylomicron (CM), very low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL)[9].

The liver, as the main regulator of lipid metabolism, assembles VLDLs and secretes them into circulation, where they are catabolized by lipoprotein lipase (LPL) to IDL. In this process, TG in the core of VLDL is hydrolyzed and delivers free fatty acids to the peripheral tissues. While most IDL is cleared by the liver, some is converted to LDL by hepatic triglyceride lipase (HTGL). LDL is incorporated into the liver or the peripheral tissue through LDL receptors[10].

Previous investigations revealed that HCV co-opts the VLDL assembly, maturation, degradation, and secretory machinery in liver cells[11,12]. HCV particles associate with lipoproteins to form lipo-viral particles (LVP) and acquire infectivity[13]. Every 24 h, 1018 VLDL particles are produced, and 1012 HCV virions are secreted from the liver[14,15].

Although the number of serum lipoprotein particles must be determined to understand lipoprotein metabolism, it has not been examined in HCV infection, mainly because measuring the number of lipoprotein particles is challenging. However, very recently, it became possible to accurately estimate the number of serum lipoprotein particles by using data derived from LipoSEARCH (Skylight Biotech, Akita, Japan). In this study, we investigated whether the number of lipoprotein particles differed between patients with active HCV genotype 1b (G1b) infection and those with cleared HCV infection using this newly developed algorithm.

**MATERIALS AND METHODS**

***Patient population***

We enrolled 173 Japanese patients with chronic HCV G1b infection or with cleared chronic HCV infection through interferon (IFN)-based therapy who were treated at Jikei University Katsushika Medical Center from July 2013 to June 2015. Patients who exhibited decompensated cirrhosis, hepatocellular carcinoma, other types of hepatitis, co-infection with other viruses, and habitual alcohol abuse or had been treated for dyslipidemia or diabetes were excluded from this study. In addition, patients who had received antiviral therapy within 6 months of the time of enrollment were excluded.

Of the 173 patients, 82 were chronically infected with HCV G1b, and 91 patients were classified as sustained virological response (SVR) based on undetectable HCV-RNA using the COBAS® Ampliprep/COBAS® TaqMan® HCV Test, v2.0 (Roche Molecular Diagnostics) at least 24 wk after completing IFN-based antiviral therapy. The HCV genotypes of enrolled patients were determined using the method described by Okamoto *et al*[16]. The HCV genotypes of the SVR patients were determined before antiviral therapy: 58 cases were designated HCV G1b, and 32 were designated HCV G2. The genotype of the one remaining patient was not known.

Written informed consent was obtained from all patients who enrolled in this study. This study was conducted with the approval of the ethics committee of the Jikei Medical University and complied with the Helsinki Declaration 2004.

***Study design***

Peripheral blood was obtained after overnight fasting for at least 10 h. Basic laboratory tests and serum lipid profiles were examined. In addition, serum lipoprotein was fractionated into 20 fractions by high-performance liquid chromatography (HPLC), and the cholesterol and TG concentration in each fraction was measured using LipoSEARCH. The number of lipoprotein particles in each fraction was calculated using the algorithm developed by Skylight Biotech, and the effect of chronic HCV G1b infection on the number of lipoprotein particles was determined by multiple linear regression analysis.

***Demographic data and basic laboratory tests***

Basic laboratory tests were performed to determine the levels of clinical markers including aspartate 2-oxoglutarate aminotransferase (AST), alanine 2-oxoglutarate aminotransferase (ALT), γ-glutamyl transpeptidase (γ-GTP), albumin, total bilirubin, platelet count, and HbA1c. Demographic data including age, gender, and body mass index (BMI) were collected from the medical record of each patient.

***Serum lipid profiles***

Total cholesterol, TG, and HDL cholesterol were directly assayed using a commercially available kit (Kyowa Medex, Tokyo, Japan). The concentration of LDL cholesterol was calculated using the Friedewald equation.

***Number of lipoprotein particles in lipoprotein fractions***

The number of lipoprotein particles in each HPLC fraction was calculated according to the newly developed algorithm. This program is based on the assumption that the volume ratio of the surface layer to lipid core is equivalent for lipoproteins with the same particle size, as previously described for oil droplets[17,18]. The detailed algorithm for determining the lipoprotein number is presented in the international register of patents (https://patentscope.wipo.int/search/; patent number: WO2015/152371).

The numbers of particles in the major lipoprotein classes were expressed as the sum of fractions 3–7 for VLDL, the sum of fractions 8–13 for LDL, and the sum of fractions 14–20 for HDL. In addition, VLDL was subdivided into three subclasses (fractions 3–5: large VLDL, fraction 6: medium VLDL, and fraction 7: small VLDL). Similarly, LDL was subdivided into four subclasses (fraction 8: large LDL, fraction 9: medium LDL, fractions 10–11: small LDL, and fractions 12–13: very small LDL), and HDL into three (fractions 14–16: large HDL, fraction 17: medium HDL, and fractions 18–20: small HDL). The particle size for each major lipoprotein class and subclass is shown in Table 1.

***Statistical analysis***

We performed the χ2 test or Mann-Whitney U test to compare categorical or continuous data between the two groups because the data deviated considerably from a Gaussian distribution. Although some clinical data in our study did not strongly deviate from a Gaussian distribution, other clinical data were not normally distributed. Thus, we applied a non-parametric test to all data.

To determine the effect of chronic active HCV infection on the number of lipoprotein particles in each major class or subclass, multiple regression models were generated considering each major class (VLDL, LDL, and HDL) or subclass as a dependent variable. We selected nine values including age, gender, BMI, ALT, γ-GTP, albumin, platelet count, HbA1c, and HCV infection status (active or cleared) as candidate independent variables. Categorical data were assigned as 0 (male, cleared HCV infection) or 1 (female, active HCV infection).

All statistical analyses were performed using STATISTICA software, version 6 (StatSoft Japan Inc. Tokyo, Japan). Two-tailed *P* < 0.05 was considered significant, while 0.05 < *P* < 0.1 was marginal. *P* values less than 0.001 were expressed as *P* < 0.001.

**RESULTS**

***Features of the active HCV group and SVR group***

The clinical features of the active HCV group and the SVR group are summarized in Table 2. The median age of the active HCV group was 69.0 years, which was significantly higher than that of SVR group (*P* = 0.048). The difference in gender between the two groups was marginal. There were no significant differences in other demographic data including BMI. In the routine laboratory tests, AST, ALT, and γ-GTP levels were significantly higher in the active HCV group than in the SVR group, whereas albumin levels and platelet counts were lower in the active HCV group. In sera, total cholesterol and LDL cholesterol were significantly lower in the active HCV group than in the SVR group, and there were no differences in TG and HDL cholesterol levels between the two groups (Table 2).

***Effect of active HCV G1b infection on the numbers of lipoprotein particles***

The numbers of LDL particles (median and interquartile range (IQR): 1182 nmol/L and 444 nmol/L *vs* 1363 nmol/L and 472 nmol/L, *P* < 0.001) and HDL particles (14168 nmol/L and 4114 nmol/L *vs* 15054 nmol/L and 3385 nmol/L, *P* = 0.042) were significantly lower in the active HCV group than in the SVR group, respectively. On the other hand, the number of VLDL particles (median and IQR: 127 nmol/L and 67 nmol/L *vs* 132 nmol/L and 64 nmol/L, *P* = 0.477) was similar between the two groups (Figure 1).

Multiple linear regression analysis of the factors that significantly influenced the number of lipoprotein particles indicated that HCV G1b infection was associated with the decreased number of LDL particles. However, HCV G1b infection did not affect the VLDL or HDL particle numbers. Other factors that affected the number of LDL particles were age, albumin, and gender. BMI, FBS, and platelet count were not associated with the LDL particle number. We did not identify a factor that significantly influenced the number of VLDL particles. For HDL particles, gender, ALT, albumin, and platelet count were identified as significantly associated factors (Table 3).

***Effect of active HCV G1b infection on the particle numbers for LDL subclasses***

In a further analysis of the number of lipoprotein particles in four LDL sub-fractions, the number of large LDL particles was similar for the active HCV group and SVR group (median and IQR: 281.1 nmol/L and 83.2 nmol/L *vs* 272.9 nmol/L and 101.6 nmol/L, respectively, *P* = 0.415). The numbers of medium (533.0 nmol/L and 214.7 nmol/L *vs* 633.5 nmol/L and 229.6 nmol/L, *P* < 0.001), small (190.9 nmol/L and 152.4 nmol/L *vs* 263.2 nmol/L and 159.9 nmol/L, *P* < 0.001), and very small LDL particles (103.5 nmol/L and 66.8 nmol/L *vs* 139.3 nmol/L and 67.3 nmol/L, *P* < 0.001) were significantly lower in the active HCV group than in the SVR group, respectively (Figure 2).

By multiple regression analysis, HCV G1b infection independently associated with the decreased numbers of medium, small, and very small LDL particles; however, it did not affect the number of large LDL particles. The albumin level also significantly correlated with the numbers of medium, small, and very small LDL particles. Female gender positively correlated with the number of large LDL particles (Table 4).

***Effect of active HCV G1b infection on the particle numbers for VLDL and HDL subclasses***

In the three VLDL sub-fractions, between the HCV group and SVR group, respectively, the number of large VLDL particles (median and IQR: 16.3 nmol/L and 16.9 nmol/L *vs* 23.2 nmol/L and 27.3 nmol/L, *P* < 0.001) was lower in the HCV group, whereas that of small VLDL particles (68.3 nmol/L and 24.9 nmol/L *vs* 59.5 nmol/L and 29.8 nmol/L *P* = 0.004) was higher in the active HCV group; the number of medium VLDL particles (37.8 nmol/L and 26.5 nmol/L *vs* 43.0 nmol/L and 34.5 nmol/L, *P* = 0.168) was similar for the two groups (Figure 3).

For the HDL sub-fractions, the number of large HDL particles (median and IQR: 2434 nmol/L and 1678 nmol/L *vs* 1953 nmol/L and 1522 nmol/L, *P* = 0.060) tended to be higher in the HCV group than in the SVR group, respectively. The numbers of medium (3618 nmol/L anad 1274 nmol/L *vs* 4187 nmol/L and 1657 nmol/L, *P* = 0.002) and small HDL particles (7926 nmol/L and 2401 nmol/L *vs* 8586 nmol/L and 2120 nmol/L, *P* = 0.005) were significantly lower in the active HCV group than in the SVR group, respectively (Figure 4).

Multiple regression analysis for the sub-fractionated VLDL particles indicated that HCV G1b did not affect the particle number of any VLDL subclass. Female gender was associated with decreased numbers of large and small VLDL particles, and albumin was positively associated with the number of small VLDL particles (Table 5). In addition, HCV G1b infection was not associated with the number of particles in any of the HDL sub-fractions. Instead,　female gender was positively associated with the numbers of large and medium HDL particles. BMI and platelet count affected the number of large HDL particles, age and ALT affected the number of medium HDL particles, and age and albumin affected the number of small HDL particles (Table 6).

**DISCUSSION**

HCV infection has been associated with biased lipid metabolism[19-24]. Because lipids are transported to the peripheral tissues in the blood as lipoprotein particles and HCV acquires infectivity as LVPs, it is important to investigate the number of lipoprotein particles in the sera of patients with HCV infection. Although the number of LDL particles can be measured by SpectraCell’s LPP™ test (https://www.**spectracell.**com/clinicians/products/**lpp)**, there have been no reports about changes in lipoprotein particle numbers during HCV infection. One reason for this lack is the methodological difficulty of accurately measuring the number of lipoprotein particles for all classes of lipoproteins[25].However, a new algorithm allows exact calculation of the number of lipoprotein particles in all major classes.

Using this algorithm, we found that the number of LDL particles, specifically the numbers of medium, small, and very small LDL particles, was decreased in patients with active HCV G1b infection. As an independent factor, HCV infection significantly influenced the numbers of these particles in multiple linear regression analysis but had no concomitant effect on the number of large LDL particles or the numbers of VLDL and HDL particles.

The heterogeneity of LDL size and density is well established[26]. LDL is derived from delipidation of VLDL through IDL (by HTGL and LPL, respectively). Parallel pathways that generate LDLs with different sizes and densities are thought to occur through different VLDLs in this VLDL-IDL-LDL cascade[27,28]. In animal models, independent pathways to generate each LDL subclass were suggested[29-31]. Sufficient TG is required to sustain lipolysis and enable the metabolism of VLDL to IDL and LDL. Thus, the amount of TG in VLDL is one determinant of LDL particle size, and it was hypothesized that TG-rich large VLDL1 was a precursor of smaller LDL[32]. A relationship between large VLDL and small, dense LDL in human was demonstrated previously[33], potentially involving CE transfer protein (CETP) and HTGL. In hypertriglyceridemia, in which TG-rich VLDL1 is increased, CETP transports CE from LDL to VLDL1 and TG from VLDL1 to LDL. This lipid exchange results in an increase of TG-rich LDL, which is hydrolyzed by HTGL into small, dense LDL[34]. The plasma TG level is dependent on VLDL1 levels[35] and positively correlates with small, dense LDL levels[36-38]. On the other hand, decreasing the activity of HTGL resulted in increased numbers of larger LDL particles[39,40]. Thus, generation of small LDL particles may be prescribed by the level of TG in VLDL and the activities of CETP and HTGL.

Previously, LPL and HTGL were shown to reduce the infectivity of HCV[41]. Therefore, for persistent HCV infection, it is preferable to avoid catabolism of HCV-LVP by LPL and HTGL. In HCV infection, the activity of HTGL is reduced through transcriptional downregulation[42]. Furthermore, we previously investigated serum TG profiles in HCV G1b infection and found that HCV infection is associated with a low level of large VLDL-TG[43]. Therefore, the decreased numbers of medium, small, and very small LDL particles might be due to a decreased amount of TG in large VLDL and reduced activity of HTGL. However, HCV G1b infection did not affect the number of large VLDL particles. Therefore, HCV G1b infection might suppress the transport of TG into VLDL without impairing the secretion of VLDL particles.

It has been reported that small, dense LDL is associated with increased risk of myocardial infarction[44,45]. Atherosclerotic plaques can be formed by oxidation of LDL particles[46]. Small, dense LDL has lower affinity to LDL receptors than larger LDL particles, resulting in longer retention in the blood and increased susceptibility to oxidative stress[47]. Moreover, small, dense LDL was more easily taken up into arterial walls through binding to polyanionic proteoglycans, resulting in induction of atherosclerosis[48]. Thus, small, dense LDL is thought to be a risk factor for atherosclerosis, and the number of LDL particles is considered a better predictor of cardiovascular events than LDL-cholesterol concentrations[49,50].

The reduced number of small LDL particles in HCV G1b infection strongly suggested that small, dense LDL do not play a major role in atherosclerosis for patients with chronic HCV G1b infection. Although the association between atherosclerosis and HCV infection has been investigated, the results are conflicting. Some studies indicated that HCV infection accelerated atherosclerosis[51-54], whereas others found no relationship between HCV infection and atherosclerosis or cardiovascular event[55-57]. HCV infection activates T helper cells and releases a number of pro-inflammatory cytokines[58], which might accelerate atherosclerosis, as chronic inflammation is a factor preceding atherosclerosis[59]. In addition, HCV infection induces insulin resistance and evokes diabetes mellitus and metabolic syndrome[60,61], which could be related to atherosclerosis in HCV patients[62]. Furthermore, increased levels of remnant lipoprotein could have a role in atherosclerosis during HCV infection[43]. Further study is required to assess the effect of the reduced number of small LDL particles on atherosclerosis in chronic HCV infection.

Although the accuracy of the lipoprotein particle calculation has been demonstrated in healthy individuals, it has not been directly demonstrated in patients with chronic HCV infection. However, we believe that this calculation method would not introduce error in the accuracy of our results that would alter our conclusions. Additionally, we emphasize that we investigated only patients with HCV G1b infection, and it is unclear whether these results are extensible to patients with other HCV genotypes.

In conclusion, HCV G1b infection is associated with decreased numbers of medium, small, and very small LDL particles. To the best of our knowledge, this is the first such report of the link between HCV and lipoprotein particle numbers.

**ACKNOWLEDGEMENTS**

We thank all the staff of Central Clinical Laboratory, Jikei University Katsushika Medical Center for excellent technical assistance.

**COMMENTS**

***Background***

Hepatitis C virus (HCV) infection was reported to alter host lipid metabolism based on observations that patients with chronic HCV have lower serum cholesterol levels, which is associates with liver steatosis. Furthermore, previous studies indicated that persistent HCV infection utilizes the very low-density lipoprotein (VLDL) assembly, maturation, degradation, and secretory machinery of liver cells.

***Research frontiers***

Although investigation of the number of serum lipoprotein particles is required to understand lipoprotein metabolism, it has not been examined in HCV infection, mainly because of it is difficult to measure. However, very recently, accurate estimation of the number of serum lipoprotein particles became possible by using the data derived from LipoSEARCH (Skylight Biotech, Akita, Japan).

***Innovations and breakthroughs***

To the best of the authors’ knowledge, this is the first study to examine the number of serum lipoprotein particles in patients with chronic HCV infection. The results of the present study are indispensible for improving our understanding of HCV-induced disruption of lipoprotein metabolism.

***Applications***

The decreased number of LDL particles in patients with HCV infection might help elucidate the mechanism of progressing atherosclerosis in patients with chronic HCV.

***Peer-review***

The topic of the current study is very promising, the authors efficiently selected the aim of this research. Whereas, HCV infection was previously reported to alter the serum lipid and lipoprotein profiles. These changes may have a new role in the parthenogenesis of HCV. This finding also may provide a new perspective on the association between HCV infection and atherosclerosis.

**REFERENCES**

1 **Dai CY**, Chuang WL, Ho CK, Hsieh MY, Huang JF, Lee LP, Hou NJ, Lin ZY, Chen SC, Hsieh MY, Wang LY, Tsai JF, Chang WY, Yu ML. Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study. *J Hepatol* 2008; **49**: 9-16 [PMID: 18486265 DOI: 10.1016/j.jhep.2008.03.016]

2 **Rubbia-Brandt L**, Quadri R, Abid K, Giostra E, Malé PJ, Mentha G, Spahr L, Zarski JP, Borisch B, Hadengue A, Negro F. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. *J Hepatol* 2000; **33**: 106-115 [PMID: 10905593 DOI: 10.1016/S0168-8278(00)80166-X]

3 **Negro F**, Sanyal AJ. Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data. *Liver Int* 2009; **29 Suppl 2**: 26-37 [PMID: 19187070 DOI: 10.1111/j.1478-3231.2008.01950.x]

4 **Lerat H**, Higgs M, Pawlotsky JM. Animal models in the study of hepatitis C virus-associated liver pathologies. *Expert Rev Gastroenterol Hepatol* 2011; **5**: 341-352 [PMID: 21651352 DOI: 10.1586/egh.11.14]

5 **Tanaka N**, Moriya K, Kiyosawa K, Koike K, Gonzalez FJ, Aoyama T. PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. *J Clin Invest* 2008; **118**: 683-694 [PMID: 18188449 DOI: 10.1172/JCI33594]

6 **Huang H**, Sun F, Owen DM, Li W, Chen Y, Gale M, Ye J. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. *Proc Natl Acad Sci U S A* 2007; **104**: 5848-5853 [PMID: 17376867 DOI: 10.1073/pnas.0700760104]

7 **Meunier JC**, Russell RS, Engle RE, Faulk KN, Purcell RH, Emerson SU. Apolipoprotein c1 association with hepatitis C virus. *J Virol* 2008; **82**: 9647-9656 [PMID: 18667498 DOI: 10.1128/JVI.00914-08]

8 **Sainz B**, Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, Yu X, Chayama K, Alrefai WA, Uprichard SL. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. *Nat Med* 2012; **18**: 281-285 [PMID: 22231557 DOI: 10.1038/nm.2581]

9 **Bassendine MF**, Sheridan DA, Felmlee DJ, Bridge SH, Toms GL, Neely RD. HCV and the hepatic lipid pathway as a potential treatment target. *J Hepatol* 2011; **55**: 1428-1440 [PMID: 21718665 DOI: 10.1016/j.jhep.2011.06.004]

10 **Packard CJ**, Munro A, Lorimer AR, Gotto AM, Shepherd J. Metabolism of apolipoprotein B in large triglyceride-rich very low density lipoproteins of normal and hypertriglyceridemic subjects. *J Clin Invest* 1984; **74**: 2178-2192 [PMID: 6511922 DOI: 10.1172/JCI111644]

11 **Ye J**. Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus. *PLoS Pathog* 2007; **3**: e108 [PMID: 17784784 DOI: 10.1371/journal.ppat.0030108]

12 **Gastaminza P**, Cheng G, Wieland S, Zhong J, Liao W, Chisari FV. Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. *J Virol* 2008; **82**: 2120-2129 [PMID: 18077707 DOI: 10.1128/JVI.02053-07]

13 **Diaz O**, Delers F, Maynard M, Demignot S, Zoulim F, Chambaz J, Trépo C, Lotteau V, André P. Preferential association of Hepatitis C virus with apolipoprotein B48-containing lipoproteins. *J Gen Virol* 2006; **87**: 2983-2991 [PMID: 16963757 DOI: 10.1099/vir.0.82033-0]

14 **Blasiole DA**, Davis RA, Attie AD. The physiological and molecular regulation of lipoprotein assembly and secretion. *Mol Biosyst* 2007; **3**: 608-619 [PMID: 17700861 DOI: 10.1039/B700706J]

15 **Neumann AU**, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. *Science* 1998; **282**: 103-107 [PMID: 9756471 DOI: 10.1126/science.282.5386.103]

16 **Okamoto H**, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, Tanaka T, Sato K, Tsuda F, Miyakawa Y, Mayumi M. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. *J Gen Virol* 1992; **73**: 673-679 [PMID: 1312125 DOI: 10.1099/0022-1317-73-3-673]

17 **Yang CY**, Gu ZW, Weng SA, Kim TW, Chen SH, Pownall HJ, Sharp PM, Liu SW, Li WH, Gotto AM. Structure of apolipoprotein B-100 of human low density lipoproteins. *Arteriosclerosis* 1989; **9**: 96-108 [PMID: 2912424 DOI: 10.1161/01.ATV.9.1.96]

18 **Schumaker VN**, Phillips ML, Chatterton JE. Apolipoprotein B and low-density lipoprotein structure: implications for biosynthesis of triglyceride-rich lipoproteins. *Adv Protein Chem* 1994; **45**: 205-248 [PMID: 8154370 DOI: 10.1016/S0065-3233(08)60641-5]

19 **Maggi G**, Bottelli R, Gola D, Perricone G, Posca M, Zavaglia C, Ideo G. Serum cholesterol and chronic hepatitis C. *Ital J Gastroenterol* 1996; **28**: 436-440 [PMID: 9032585]

20 **Fabris C**, Federico E, Soardo G, Falleti E, Pirisi M. Blood lipids of patients with chronic hepatitis: differences related to viral etiology. *Clin Chim Acta* 1997; **261**: 159-165 [PMID: 9201435 DOI: 10.1016/S0009-8981(97)06532-7]

21 **Targett-Adams P**, Hope G, Boulant S, McLauchlan J. Maturation of hepatitis C virus core protein by signal peptide peptidase is required for virus production. *J Biol Chem* 2008; **283**: 16850-16859 [PMID: 18424431 DOI: 10.1074/jbc.M802273200]

22 **Gastaminza P**, Kapadia SB, Chisari FV. Differential biophysical properties of infectious intracellular and secreted hepatitis C virus particles. *J Virol* 2006; **80**: 11074-11081 [PMID: 16956946 DOI: 10.1128/JVI.01150-06]

23 **Nielsen SU**, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL. Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. *J Virol* 2006; **80**: 2418-2428 [PMID: 16474148 DOI: 10.1128/JVI.80.5.2418-2428.2006]

24 **Perlemuter G**, Sabile A, Letteron P, Vona G, Topilco A, Chrétien Y, Koike K, Pessayre D, Chapman J, Barba G, Bréchot C. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. *FASEB J* 2002; **16**: 185-194 [PMID: 11818366 DOI: 10.1096/fj.01-0396com]

25 **Kathiresan S**, Otvos JD, Sullivan LM, Keyes MJ, Schaefer EJ, Wilson PW, D'Agostino RB, Vasan RS, Robins SJ. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. *Circulation* 2006; **113**: 20-29 [PMID: 16380547 DOI: 10.1161/CIRCULATIONAHA.105.567107]

26 **Krauss RM**, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. *J Lipid Res* 1982; **23**: 97-104 [PMID: 7057116]

27 **Packard CJ**, Gaw A, Demant T, Shepherd J. Development and application of a multicompartmental model to study very low density lipoprotein subfraction metabolism. *J Lipid Res* 1995; **36**: 172-187 [PMID: 7706942]

28 **Gaw A**, Packard CJ, Caslake MJ, Griffin BA, Lindsay GM, Thomson J, Vallance BD, Wosornu D, Shepherd J. Effects of ciprofibrate on LDL metabolism in man. *Atherosclerosis* 1994; **108**: 137-148 [PMID: 7980713 DOI: 10.1016/0021-9150(94)90108-2]

29 **Fidge NH**, Poulis P. Metabolic heterogeneity in the formation of low density lipoprotein from very low density lipoprotein in the rat: evidence for the independent production of a low density lipoprotein subfraction. *J Lipid Res* 1978; **19**: 342-349 [PMID: 206639]

30 **Johnson FL**, St Clair RW, Rudel LL. Studies on the production of low density lipoproteins by perfused livers from nonhuman primates. Effect of dietary cholesterol. *J Clin Invest* 1983; **72**: 221-236 [PMID: 6874948 DOI: 10.1172/JCI110961]

31 **Cooper ST**, Aiello RJ, Checovich WJ, Attie AD. Low density lipoprotein heterogeneity in spontaneously hypercholesterolemic pigs. *Mol Cell Biochem* 1992; **113**: 133-140 [PMID: 1518504 DOI: 10.1007/BF00231533]

32 **Berneis KK**, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. *J Lipid Res* 2002; **43**: 1363-1379 [PMID: 12235168 DOI: 10.1194/jlr.R200004-JLR200]

33 **Packard CJ**, Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. *Arterioscler Thromb Vasc Biol* 1997; **17**: 3542-3556 [PMID: 9437204 DOI: 10.1161/01.ATV.17.12.3542]

34 **Kolovou GD**, Anagnostopoulou KK, Kostakou PM, Mikhailidis DP. Cholesterol ester transfer protein (CETP), postprandial lipemia and hypolipidemic drugs. *Curr Med Chem* 2009; **16**: 4345-4360 [PMID: 19835569 DOI: 10.2174/092986709789712853]

35 **Tan CE**, Foster L, Caslake MJ, Bedford D, Watson TD, McConnell M, Packard CJ, Shepherd J. Relations between plasma lipids and postheparin plasma lipases and VLDL and LDL subfraction patterns in normolipemic men and women. *Arterioscler Thromb Vasc Biol* 1995; **15**: 1839-1848 [PMID: 7583563 DOI: 10.1161/01.ATV.15.11.1839]

36 **Austin MA**, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. *Circulation* 1990; **82**: 495-506 [PMID: 2372896 DOI: 10.1161/01.CIR.82.2.495]

37 **Campos H**, Genest JJ, Blijlevens E, McNamara JR, Jenner JL, Ordovas JM, Wilson PW, Schaefer EJ. Low density lipoprotein particle size and coronary artery disease. *Arterioscler Thromb* 1992; **12**: 187-195 [PMID: 1543692 DOI: 10.1161/01.ATV.12.2.187]

38 **McNamara JR**, Jenner JL, Li Z, Wilson PW, Schaefer EJ. Change in LDL particle size is associated with change in plasma triglyceride concentration. *Arterioscler Thromb* 1992; **12**: 1284-1290 [PMID: 1420088 DOI: 10.1161/01.ATV.12.11.1284]

39 **Zambon A**, Austin MA, Brown BG, Hokanson JE, Brunzell JD. Effect of hepatic lipase on LDL in normal men and those with coronary artery disease. *Arterioscler Thromb* 1993; **13**: 147-153 [PMID: 8427851 DOI: 10.1161/01.ATV.13.2.147]

40 **Watson TD**, Caslake MJ, Freeman DJ, Griffin BA, Hinnie J, Packard CJ, Shepherd J. Determinants of LDL subfraction distribution and concentrations in young normolipidemic subjects. *Arterioscler Thromb* 1994; **14**: 902-910 [PMID: 8199180 DOI: 10.1161/01.ATV.14.6.902]

41 **Shimizu Y**, Hishiki T, Sugiyama K, Ogawa K, Funami K, Kato A, Ohsaki Y, Fujimoto T, Takaku H, Shimotohno K. Lipoprotein lipase and hepatic triglyceride lipase reduce the infectivity of hepatitis C virus (HCV) through their catalytic activities on HCV-associated lipoproteins. *Virology* 2010; **407**: 152-159 [PMID: 20822787 DOI: 10.1016/j.virol.2010.08.011]

42 **Shinohara Y**, Imajo K, Yoneda M, Tomeno W, Ogawa Y, Fujita K, Kirikoshi H, Takahashi J, Funakoshi K, Ikeda M, Kato N, Nakajima A, Saito S. Hepatic triglyceride lipase plays an essential role in changing the lipid metabolism in genotype 1b hepatitis C virus replicon cells and hepatitis C patients. *Hepatol Res* 2013; **43**: 1190-1198 [PMID: 23607715 DOI: 10.1111/hepr.12072]

43 **Nagano T**, Seki N, Tomita Y, Sugita T, Aida Y, Itagaki M, Sutoh S, Abe H, Tsubota A, Aizawa Y. Impact of Chronic Hepatitis C Virus Genotype 1b Infection on Triglyceride Concentration in Serum Lipoprotein Fractions. *Int J Mol Sci* 2015; **16**: 20576-20594 [PMID: 26334270 DOI: 10.3390/ijms160920576]

44 **Tornvall P**, Karpe F, Carlson LA, Hamsten A. Relationships of low density lipoprotein subfractions to angiographically defined coronary artery disease in young survivors of myocardial infarction. *Atherosclerosis* 1991; **90**: 67-80 [PMID: 1799399 DOI: 10.1016/0021-9150(91)90245-X]

45 **Austin MA**, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. *JAMA* 1988; **260**: 1917-1921 [PMID: 3418853 DOI: 10.1001/jama.1988.03410130125037]

46 **Hong D**, Bai YP, Gao HC, Wang X, Li LF, Zhang GG, Hu CP. Ox-LDL induces endothelial cell apoptosis via the LOX-1-dependent endoplasmic reticulum stress pathway. *Atherosclerosis* 2014; **235**: 310-317 [PMID: 24911634 DOI: 10.1016/j.atherosclerosis.2014.04.028]

47 **Chen GC**, Liu W, Duchateau P, Allaart J, Hamilton RL, Mendel CM, Lau K, Hardman DA, Frost PH, Malloy MJ. Conformational differences in human apolipoprotein B-100 among subspecies of low density lipoproteins (LDL). Association of altered proteolytic accessibility with decreased receptor binding of LDL subspecies from hypertriglyceridemic subjects. *J Biol Chem* 1994; **269**: 29121-29128 [PMID: 7961878]

48 **Rizzo M**, Berneis K. Should we measure routinely the LDL peak particle size? *Int J Cardiol* 2006; **107**: 166-170 [PMID: 16412793 DOI: 10.1016/j.ijcard.2005.02.035]

49 **Cole TG**, Contois JH, Csako G, McConnell JP, Remaley AT, Devaraj S, Hoefner DM, Mallory T, Sethi AA, Warnick GR. Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices. *Clin Chem* 2013; **59**: 752-770 [PMID: 23386699 DOI: 10.1373/clinchem.2012.196733]

50 **Toth PP**, Grabner M, Punekar RS, Quimbo RA, Cziraky MJ, Jacobson TA. Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets. *Atherosclerosis* 2014; **235**: 585-591 [PMID: 24956532 DOI: 10.1016/j.atherosclerosis.2014.05.914]

51 **Vassalle C**, Masini S, Bianchi F, Zucchelli GC. Evidence for association between hepatitis C virus seropositivity and coronary artery disease. *Heart* 2004; **90**: 565-566 [PMID: 15084562 DOI: 10.1136/hrt.2003.018937]

52 **Ishizaka Y**, Ishizaka N, Takahashi E, Unuma T, Tooda E, Hashimoto H, Nagai R, Yamakado M. Association between hepatitis C virus core protein and carotid atherosclerosis. *Circ J* 2003; **67**: 26-30 [PMID: 12520147 DOI: 10.1253/circj.67.26]

53 **Ishizaka N**, Ishizaka Y, Takahashi E, Tooda Ei, Hashimoto H, Nagai R, Yamakado M. Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. *Lancet* 2002; **359**: 133-135 [PMID: 11809259 DOI: 10.1016/S0140-6736(02)07339-7]

54 **Hsu YC**, Lin JT, Ho HJ, Kao YH, Huang YT, Hsiao NW, Wu MS, Liu YY, Wu CY. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. *Hepatology* 2014; **59**: 1293-1302 [PMID: 24122848 DOI: 10.1002/hep.26892]

55 **Arcari CM**, Nelson KE, Netski DM, Nieto FJ, Gaydos CA. No association between hepatitis C virus seropositivity and acute myocardial infarction. *Clin Infect Dis* 2006; **43**: e53-e56 [PMID: 16912934 DOI: 10.1086/507031]

56 **Kiechl S**, Egger G, Mayr M, Wiedermann CJ, Bonora E, Oberhollenzer F, Muggeo M, Xu Q, Wick G, Poewe W, Willeit J. Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. *Circulation* 2001; **103**: 1064-1070 [PMID: 11222467 DOI: 10.1161/01.CIR.103.8.1064]

57 **Forde KA**, Haynes K, Troxel AB, Trooskin S, Osterman MT, Kimmel SE, Lewis JD, Lo Re V. Risk of myocardial infarction associated with chronic hepatitis C virus infection: a population-based cohort study. *J Viral Hepat* 2012; **19**: 271-277 [PMID: 22404725 DOI: 10.1111/j.1365-2893.2011.01545.x]

58 **Gershon AS**, Margulies M, Gorczynski RM, Heathcote EJ. Serum cytokine values and fatigue in chronic hepatitis C infection. *J Viral Hepat* 2000; **7**: 397-402 [PMID: 11115049 DOI: 10.1046/j.1365-2893.2000.00249.x]

59 **Libby P**, Ridker PM, Maseri A. Inflammation and atherosclerosis. *Circulation* 2002; **105**: 1135-1143 [PMID: 11877368 DOI: 10.1161/hc0902.104353]

60 **Shintani Y**, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, Moriya K, Koike K. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. *Gastroenterology* 2004; **126**: 840-848 [PMID: 14988838 DOI: 10.1053/j.gastro.2003.11.056]

61 **Vanni E**, Abate ML, Gentilcore E, Hickman I, Gambino R, Cassader M, Smedile A, Ferrannini E, Rizzetto M, Marchesini G, Gastaldelli A, Bugianesi E. Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. *Hepatology* 2009; **50**: 697-706 [PMID: 19582803 DOI: 10.1002/hep.23031]

62 **Haberka M**, Gąsior Z. Carotid extra-media thickness in obesity and metabolic syndrome: a novel index of perivascular adipose tissue: extra-media thickness in obesity and metabolic syndrome. *Atherosclerosis* 2015; **239**: 169-177 [PMID: 25617857 DOI: 10.1016/j.atherosclerosis.2014.12.058]

**P-Reviewer:** Gabr SA, Rizk SM **S-Editor:** Yu J **L-Editor:** **E-Editor:**

**Figure 1 Comparison of the particle numbers of the three major lipoprotein classes for the active hepatitis C virus and sustained virological response groups.** HCV: Hepatitis C virus; SVR: Sustained virological response.

**Figure 2 Comparison of the particle numbers of the four** low-density lipoprotein **subclasses for the active hepatitis C virus and sustained virological response groups.** HCV: Hepatitis C virus; SVR: Sustained virological response; LDL: Low-density lipoprotein.

**Figure 3 Comparison of the particle numbers of the three very low-density lipoprotein subclasses for the active hepatitis C virus and sustained virological response groups.** HCV: Hepatitis C virus; SVR: Sustained virological response; VLDL: Very low-density lipoprotein.

**Figure 4 Comparison of the particle numbers of the three high-density lipoprotein subclasses for the active hepatitis C virus and Sustained virological response groups.** HCV: Hepatitis C virus; SVR: Sustained virological response.

**Table 1 Particle sizes in each major lipoprotein class and subclass.**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Particle size (nm)** | **Major class** | **Subclass** |
| 1 | > 90 | CM | - |
| 2 | 75 |
| 3 | 64 | VLDL | large VLDL |
| 4 | 53.6 |
| 5 | 44.5 |
| 6 | 36.8 | medium VLDL |
| 7 | 31.3 | small VLDL |
| 8 | 28.6 | LDL | large LDL |
| 9 | 25.5 | medium LDL |
| 10 | 23 | small LDL |
| 11 | 20.7 | very small LDL |
| 12 | 18.6 |
| 13 | 16.7 |
| 14 | 15 | HDL | large HDL |
| 15 | 13.5 |
| 16 | 12.1 |
| 17 | 10.9 | medium HDL |
| 18 | 9.8 | small HDL |
| 19 | 8.8 |
| 20 | 7.6 |

CM: Chylomicron; VLDL: Very low-density lipoprotein; LDL: Low-density lipoprotein; HDL: High-density lipoprotein.

**Table 2 Comparison of clinical features between patients with chronic active hepatitis C virus G1b infection (active hepatitis C virus) and cleared hepatitis C virus infection (**Sustained virological response**)**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Discrete traits** | **Active HCV** | | | | **SVR** | | | | | ***P* value** |
|  | (*n =* 82), | | | | (*n =* 91), | | | | |  |
|  | *n* (%) | | | | *n* (%) | | | | |  |
| Sex |  |  |  |  |  |  |  |  |  | 0.500 |
| Male | 36 (44) | | | | 46 (51) | | | | |  |
| Female | 46 (56) | | | | 45 (49) | | | | |  |
| **Quantitative traits** | **Median** | **(Q1** | **–** | **Q3)** |  | **Median** | **(Q1** | **–** | **Q3)** | ***P* value** |
| Age (years) | 69.0 | 63.0 | – | 74.8 |  | 65.0 | 57.0 | – | 73.0 | 0.048 |
| BMI (kg/m2) | 21.9 | 20.3 | – | 24.0 |  | 22.5 | 21.0 |  | 24.5 | 0.145 |
| HbA1c (%) | 5.5 | 5.2 | – | 5.8 |  | 5.6 | 5.4 | – | 6.0 | 0.105 |
| Glucose (mg/dL) | 105.0 | 95.0 | – | 117.0 |  | 104.0 | 95.0 | – | 114.5 | 0.800 |
| AST (IU/L) | 41.0 | 30.0 | – | 74.3 |  | 23.0 | 20.0 | – | 28.0 | < 0.001 |
| ALT (IU/L) | 36.5 | 24.8 | – | 58.5 |  | 17.0 | 13.0 | – | 23.0 | < 0.001 |
| Total bilirubin (mg/dL) | 0.7 | 0.6 | – | 0.9 |  | 0.7 | 0.5 | – | 0.8 | 0.040 |
| γ-GTP (IU/L) | 30.5 | 21.0 | – | 52.8 |  | 21.0 | 16.0 | – | 30.0 | < 0.001 |
| Albumin (g/dL) | 4.2 | 3.8 | – | 4.3 |  | 4.4 | 4.2 | – | 4.6 | < 0.001 |
| Platelet (104/μL) | 15.5 | 11.8 | – | 20.6 |  | 17.3 | 13.4 | – | 21.0 | 0.048 |
|  |  |  |  |  |  |  |  |  |  |  |
| **Lipid profiles** |  |  |  |  |  |  |  |  |  |  |
| Total cholesterol (mg/dL) | 174.5 | 151.3 | – | 192.8 |  | 193.0 | 175.5 | – | 216.5 | < 0.001 |
| Triglyceride (mg/dL) | 89.5 | 64.0 | – | 116.8 |  | 88.0 | 68.0 | – | 135.0 | 0.700 |
| LDL cholesterol (mg/dL) | 93.5 | 77.0 | – | 110.5 |  | 112.5 | 93.0 | – | 133.5 | < 0.001 |
| HDL cholesterol (mg/dL) | 59.8 | 47.3 | – | 72.2 |  | 61.7 | 51.2 | – | 74.0 | 0.195 |

HCV: Hepatitis C virus; SVR: Sustained virological response; BMI: Body mass index; AST: Aspartate 2-oxoglutarate aminotransferase; ALT: Alanine 2-oxoglutarate aminotransferase; γ-GTP: γ-Glutamyl transpeptidase; LDL: Low-density lipoprotein; HDL: High-density lipoprotein.

**Table 3 Effect of chronic active hepatitis C virus infection on particle number of serum lipoproteins analyzed by multiple regression models**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **VLDL** | | |  | **LDL** | | |  | **HDL** | | |
|  | **B** | **SE** | ***P* value** |  | **B** | **SE** | ***P* value** |  | **B** | **SE** | ***P* value** |
| Constant | 119.1 | 85.4 | 0.165 |  | -371.5 | 414.5 | 0.371 |  | 8693.2 | 3114.6 | 0.006 |
| HCV infection (Active HCV *vs* SVR) | -7.5 | 12.9 | 0.558 |  | -150.2 | 62.4 | 0.017 |  | 256.6 | 468.8 | 0.585 |
| Age | 0.3 | 0.5 | 0.583 |  | 4.8 | 2.3 | 0.041 |  | -39.4 | 17.5 | 0.026 |
| Female | -10.7 | 10.7 | 0.321 |  | 11.6 | 52.1 | 0.825 |  | 1513.1 | 391.8 | < 0.001 |
| BMI | 2.7 | 1.6 | 0.083 |  | 11.7 | 7.6 | 0.125 |  | -72.2 | 57.0 | 0.207 |
| ALT | 0.1 | 0.2 | 0.498 |  | -0.2 | 1.0 | 0.815 |  | -16.5 | 7.43 | 0.028 |
| Albumin | -13.6 | 14.6 | 0.353 |  | 213.8 | 70.8 | 0.003 |  | 2054.6 | 532.2 | < 0.001 |
| Glucose | 0.1 | 0.3 | 0.614 |  | 2.3 | 1.4 | 0.094 |  | 4.1 | 10.3 | 0.692 |
| Platelet | -0.4 | 0.5 | 0.369 |  | -0.5 | 2.2 | 0.820 |  | 37.2 | 16.4 | 0.025 |

VLDL: Very low-density lipoprotein; LDL: Low-density lipoprotein; HDL: High-density lipoprotein; SE: Standard error; HCV: Hepatitis C virus; SVR: Sustained virological response; BMI: Body mass index; ALT: Alanine 2-oxoglutarate aminotransferase.

**Table 4 Effect of chronic active hepatitis C virus infection on particle number of four low-density lipoprotein sub-fractions analyzed by multiple regression models**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Large LDL** | | |  | **Medium LDL** | | |  | **Small LDL** | | |  | **Very small LDL** | | |
|  | **B** | **SE** | ***P* value** |  | **B** | **SE** | ***P* value** |  | **B** | **SE** | ***P* value** |  | **B** | **SE** | ***P* value** |
| Constant | 206.0 | 93.4 | 0.029 |  | -263.6 | 202.3 | 0.195 |  | -274.1 | 139.6 | 0.051 |  | -39.8 | 64.6 | 0.538 |
| HCV infection (Active HCV *vs* SVR) | 0.4 | 14.1 | 0.978 |  | -66.4 | 30.5 | 0.031 |  | -55.3 | 21.0 | 0.009 |  | -28.8 | 9.7 | 0.004 |
| Age | 0.9 | 0.5 | 0.086 |  | 2.1 | 1.1 | 0.072 |  | 1.2 | 0.8 | 0.128 |  | 0.6 | 0.4 | 0.083 |
| Female | 42.6 | 11.7 | <0.001 |  | 9.2 | 25.5 | 0.719 |  | -29.7 | 17.6 | 0.093 |  | -10.5 | 8.1 | 0.198 |
| BMI | 1.7 | 1.7 | 0.308 |  | 5.0 | 3.7 | 0.177 |  | 3.7 | 2.6 | 0.151 |  | 1.2 | 1.2 | 0.297 |
| ALT | 0.1 | 0.2 | 0.584 |  | -0.1 | 0.5 | 0.823 |  | -0.1 | 0.3 | 0.726 |  | -0.1 | 0.2 | 0.404 |
| Albumin | -14.1 | 16.0 | 0.378 |  | 121.2 | 34.6 | 0.001 |  | 80.6 | 23.8 | 0.001 |  | 26.1 | 11.0 | 0.019 |
| Glucose | 0.2 | 0.3 | 0.519 |  | 1.3 | 0.7 | 0.060 |  | 0.7 | 0.5 | 0.149 |  | 0.2 | 0.2 | 0.412 |
| Platelet | -0.3 | 0.5 | 0.507 |  | -0.2 | 1.1 | 0.877 |  | 0.0 | 0.7 | 0.967 |  | -0.04 | 0.3 | 0.917 |

LDL: Low-density lipoprotein; SE: Standard error; HCV: Hepatitis C virus; SVR: Sustained virological response; BMI: Body mass index; ALT: Alanine 2-oxoglutarate aminotransferase.

**Table 5 Effect of chronic active hepatitis C virus infection on the particle number for three very low-density lipoprotein sub-fractions analyzed by multiple regression models**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Large VLDL** | | |  | **Medium VLDL** | | |  | **Small VLDL** | | |
|  | **B** | **SE** | ***P* value** |  | **B** | **SE** | ***P* value** |  | **B** | **SE** | ***P* value** |
| Constant | -18.1 | 32.1 | 0.574 |  | 21.1 | 38.9 | 0.588 |  | 116.1 | 35.0 | 0.001 |
| HCV infection (Active HCV *vs* SVR) | -6.6 | 4.8 | 0.176 |  | -4.0 | 5.9 | 0.494 |  | 3.0 | 5.3 | 0.564 |
| Age | 0.03 | 0.2 | 0.868 |  | 0.05 | 0.2 | 0.819 |  | 0.2 | 0.2 | 0.352 |
| Female | -12.7 | 4.0 | 0.002 |  | -7.2 | 4.9 | 0.145 |  | 9.1 | 4.4 | 0.040 |
| BMI | 0.9 | 0.6 | 0.126 |  | 1.1 | 0.7 | 0.122 |  | 0.7 | 0.6 | 0.263 |
| ALT | 0.01 | 0.08 | 0.878 |  | 0.03 | 0.09 | 0.750 |  | 0.1 | 0.08 | 0.247 |
| Albumin | 8.8 | 5.5 | 0.109 |  | -0.7 | 6.6 | 0.912 |  | -21.7 | 6.0 | < 0.001 |
| Glucose | -0.04 | 0.1 | 0.679 |  | 0.1 | 0.1 | 0.477 |  | 0.1 | 0.1 | 0.413 |
| Platelet | -0.02 | 0.2 | 0.903 |  | -0.2 | 0.2 | 0.355 |  | -0.2 | 0.2 | 0.294 |

VLDL: Very low-density lipoprotein; SE: Standard error; HCV: Hepatitis C virus; SVR: Sustained virological response; BMI: Body mass index; ALT: Alanine 2-oxoglutarate aminotransferase.

**Table 6 Effect of chronic active hepatitis C virus infection on the particle number for three high-density lipoprotein sub-fractions analyzed by multiple regression models**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Large HDL** | | |  | **Medium HDL** | | |  | **Small HDL** | | |
|  | **B** | **SE** | ***P* value** |  | **B** | **SE** | ***P* value** |  | **B** | **SE** | ***P* value** |
| Constant | 4544.7 | 1510.8 | 0.003 |  | 3499.5 | 1188.8 | 0.004 |  | 649.0 | 2033.7 | 0.750 |
| HCV infection (Active HCV *vs* SVR) | 345.1 | 227.4 | 0.131 |  | -106.9 | 178.9 | 0.551 |  | 18.4 | 306.1 | 0.952 |
| Age | 9.4 | 8.5 | 0.272 |  | -18.9 | 6.7 | 0.005 |  | -29.9 | 11.4 | < 0.001 |
| Female | 494.1 | 190.0 | 0.010 |  | 719.2 | 149.5 | <0.001 |  | 299.8 | 255.8 | 0.243 |
| BMI | -96.1 | 27.6 | 0.001 |  | -29.19 | 21.76 | 0.182 |  | 53.1 | 37.2 | 0.156 |
| ALT | -5.6 | 3.6 | 0.122 |  | -7.67 | 2.84 | 0.008 |  | -3.2 | 4.9 | 0.515 |
| Albumin | -136.8 | 258.2 | 0.597 |  | 361.7 | 203.1 | 0.077 |  | 1829.7 | 347.5 | < 0.001 |
| Glucose | -5.0 | 5.0 | 0.323 |  | 5.1 | 3.9 | 0.196 |  | 3.9 | 6.7 | 0.559 |
| Platelet | 19.6 | 8.0 | 0.015 |  | 9.8 | 6.3 | 0.122 |  | 7.9 | 10.7 | 0.463 |

HDL: High-density lipoprotein; SE: Standard error; HCV: Hepatitis C virus; SVR: Sustained virological response; BMI: Body mass index; ALT: Alanine 2-oxoglutarate aminotransferase.